

Electronic Acknowledgement Receipt

EFS ID:	1089640
Application Number:	10648816
Confirmation Number:	5367
Title of Invention:	Vascular endothelial cell growth factor antagonists and uses thereof
First Named Inventor:	Nicholas Van Bruggen
Customer Number:	23552
Filer:	Katherine M. Kowalchyk/Sheryl Boerboom
Filer Authorized By:	Katherine M. Kowalchyk
Attorney Docket Number:	11669.0113USC1
Receipt Date:	23-JUN-2006
Filing Date:	26-AUG-2003
Time Stamp:	10:00:03
Application Type:	Utility
International Application Number:	

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part	Pages
1	Miscellaneous Incoming Letter	Interview_Summary.pdf	30081	no	1

Warnings:

The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the Image File Wrapper and may affect subsequent processing

Information:**Total Files Size (in bytes):**

30081

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.